What's new? Log in Free sign up

Scinai Immunotherapeutics (SCNI)

Company Profile

Company profile

Ticker

SCNI

Exchange

Website

CEO

Mr. Amir Reichman M.B.A., M.Sc.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

SCNI stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Report of Foreign Private Issuer

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

ARMISTICE CAPITAL, LLC

STONE DANIEL E.

STONE DANIEL E.

ARMISTICE CAPITAL, LLC

STONE DANIEL E.

SABBY MANAGEMENT, LLC

STONE DANIEL E.

Morris C Laster

Financial summary

Financial statements Chart SCNI financial data

Quarter (USD)	Mar 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)		10.93 mm	10.93 mm	10.93 mm	10.93 mm	10.93 mm
Cash burn (monthly)		(no burn)	1.06 mm	265.50 k	1.02 mm	254.92 k
Cash used (since last report)		n/a	22.07 mm	5.52 mm	21.19 mm	5.30 mm
Cash remaining		n/a	-11.15 mm	5.41 mm	-10.27 mm	5.63 mm
Runway (months of cash)		n/a	-10.5	20.4	-10.1	22.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

SCNI institutional ownership history Ownership history

96.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	6	12	-50.0%
Opened positions	1	9	-88.9%
Closed positions	7	0	NEW
Increased positions	0	0
Reduced positions	4	0	NEW

13F shares	Current	Prev Q	Change
Total value	561.67 mm	758.20 mm	-25.9%
Total shares	170.96 mm	171.35 mm	-0.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Nacht Marius	170.96 mm	$557.34 mm	0.0%
Rhumbline Advisers	1.14 k	$3.24 mm	-82.9%
MS Morgan Stanley	255.00	$709.00 k	-90.1%
BAC Bank of America	100.00	$278.00 k	NEW
Aspire Private Capital	32.00	$89.00 k	-80.0%
Global Retirement Partners	5.00	$14.00 k	-90.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Sabby Management	0.00	-253.14 k	EXIT
Armistice Capital	0.00	-121.79 k	EXIT
Rhumbline Advisers	1.14 k	-5.52 k	-82.9%
MS Morgan Stanley	255.00	-2.32 k	-90.1%
UBS UBS	0.00	-2.12 k	EXIT
Credit Agricole S A	0.00	-424.00	EXIT
Main Street	0.00	-200.00	EXIT
Aspire Private Capital	32.00	-128.00	-80.0%
BAC Bank of America	100.00	+100.00	NEW
Global Retirement Partners	5.00	-45.00	-90.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Scinai Immunotherapeutics Announces The Establishment Of A U.S.-Based Subsidiary For Its Contract Development And Manufacturing Services

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press releases

From Benzinga Pro

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

JERUSALEM, Dec. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I)

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.